Aardvark Therapeutics Inc (AARD) has a current Price-to-Book (P/B) ratio of 2.34. Compared to its 3-year average P/B ratio of 1.28, the current P/B ratio is approximately 82.89% higher. Relative to its 5-year average P/B ratio of 1.28, the current P/B ratio is about 82.89% higher. Aardvark Therapeutics Inc (AARD) has a Forward Free Cash Flow (FCF) yield of approximately -15.74%. Compared to its 3-year average FCF yield of -12.87%, the current FCF yield is approximately 22.23% lower. Relative to its 5-year average FCF yield of -12.87%, the current FCF yield is about 22.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AARD competitors is 1.57, providing a benchmark for relative valuation. Aardvark Therapeutics Inc Corp (AARD.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AARD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AARD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AARD currently overvalued or undervalued?

What is Aardvark Therapeutics Inc (AARD) fair value?

AARD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aardvark Therapeutics Inc (AARD) is between to according to relative valuation method.

How does AARD's valuation metrics compare to the industry average?

The average P/S ratio for AARD's competitors is 1.57, providing a benchmark for relative valuation. Aardvark Therapeutics Inc Corp (AARD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Aardvark Therapeutics Inc (AARD) as of Mar 02 2026?

As of Mar 02 2026, Aardvark Therapeutics Inc (AARD) has a P/B ratio of 2.34. This indicates that the market values AARD at 2.34 times its book value.

What is the current FCF Yield for Aardvark Therapeutics Inc (AARD) as of Mar 02 2026?

As of Mar 02 2026, Aardvark Therapeutics Inc (AARD) has a FCF Yield of -15.74%. This means that for every dollar of Aardvark Therapeutics Inc's market capitalization, the company generates -15.74 cents in free cash flow.

What is the current Forward P/E ratio for Aardvark Therapeutics Inc (AARD) as of Mar 02 2026?

As of Mar 02 2026, Aardvark Therapeutics Inc (AARD) has a Forward P/E ratio of -3.83. This means the market is willing to pay $-3.83 for every dollar of Aardvark Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aardvark Therapeutics Inc (AARD) as of Mar 02 2026?

As of Mar 02 2026, Aardvark Therapeutics Inc (AARD) has a Forward P/S ratio of 0.00. This means the market is valuing AARD at $0.00 for every dollar of expected revenue over the next 12 months.

AARD Valuation